5 completed, 2 active not recruiting, 1 withdrawn. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Active not recruiting 2, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow bazedoxifene: new trials by email Literature Review of bazedoxifene trials Research Report on bazedoxifene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans Placebo, conjugated estrogens/bazedoxifene (CE/BZA) - Menopause, Prediabetes | Phase 2 | Withdrawn | VA Office of Research and Development | 2024-04-08 | 2024-05-10 | |
| Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens Bazedoxifene and Conjugated Estrogens - Risk Reduction, Breast Cancer | Phase 2 | Active not recruiting | University of Kansas Medical Center | 120 | 2021-12-14 | 2026-10-27 |
| Advancing Postmenopausal Preventive Therapy Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg, Placebo - Atherosclerosis, Cognitive Decline | Phase 2 | Active not recruiting | University of Southern California | 385 | 2021-04-13 | 2024-12-05 |
| Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis Bazedoxifene Acetate - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Completed | Riley Bove, MD | 63 | 2019-09-10 | 2025-06-08 |
| The PROMISE Study: Duavee in Women With DCIS Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study - Ductal Breast Carcinoma In Situ, Postmenopausal | Phase 2 | Completed | Northwestern University | 142 | 2017-01-01 | 2025-01-28 |
| Pilot Study of the Effect of DuaveeĀ® on Benign Breast Tissue Proliferation Duavee - Breast Cancer | Phase 2 | Completed | University of Kansas Medical Center | 28 | 2016-05-01 | 2022-03-09 |
| A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer Palbociclib, Bazedoxifene - Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 36 | 2015-07-09 | 2022-10-24 |
| Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis. Bazedoxifene, Placebo - Postmenopausal Osteoporosis | Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 375 | 2003-08-01 | 2007-12-20 |
Breast Neoplasms (3) · Hot Flashes (2) · Atherosclerosis (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Cognitive Dysfunction (1) · Diabetes Mellitus (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Obesity (1) · Osteoporosis, Postmenopausal (1) · Prediabetic State (1) · Risk Reduction Behavior (1)
University of Kansas Medical Center (2) · Dana-Farber Cancer Institute (1) · Northwestern University (1) · Riley Bove, MD (1) · University of Southern California (1) · VA Office of Research and Development (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (7)
Carol Fabian, MD (1) · Carol J Fabian, MD (1) · Dragana Lovre, MD (1) · Howard N. Hodis, MD (1) · Riley M Bove, MD MMSc (1) · Rinath Jelsohn, MD (1) · Swati Kulkarni, MD (1)
PMID 20839291, PMID 31420361, PMID 36215125, PMID 37715710, PMID 37739167, PMID 39293780
1IK2CX002225-01A1 (1), P30CA060553 (1), R01AG058691 (1), R01CA249437 (1)